TuHURA to acquire Kineta in stock/cash merger; $35M concurrent financing required

TuHURA Biosciences, Inc./NV

Consideration per Kineta share: initial stock based on $15M pool, delayed stock based on $5M, plus cash and contingent asset payment rights.
Closing requires TuHURA to raise at least $35M net proceeds from a concurrent private investment.
TuHURA will loan Kineta up to $900k at 5% interest to fund R&D expenses, secured by program assets.
Key conditions: stockholder approvals (Kineta merger vote; TuHURA authorized share increase to 200M), listing, and no law/order preventing deal.
Termination fee of $1M payable by Kineta if it accepts a superior proposal; $1M by TuHURA if it fails to close the concurrent investment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.